Phase 1 Trial: 177Lu-DGUL Plus Pembrolizumab (Keytruda) in mCRPC

/in , , /by

A pivotal clinical trial is underway to evaluate the safety and efficacy of combining Lutetium (177Lu) DGUL radioligand therapy with pembrolizumab (Keytruda) for treating metastatic castration-resistant prostate cancer in patients who have progressed after androgen receptor-targeted therapies but have not yet received chemotherapy. The study enrolls men with prostate-specific membrane antigen (PSMA)-positive tumors, with disease […]

Read more

GTB-5550: a New Tri-Specific Natural Killer Cell Engager Moving To Clinical Trials

/in , , /by

GTB-5550, a novel tri-specific natural killer (NK) cell engager drug designed to target the B7-H3 antigen has shown notable promise in advancing cancer immunotherapy for solid tumors, particularly prostate cancer and head and neck squamous cell carcinoma (HNSCC). This drug functions by simultaneously binding to CD16 on NK cells, engaging B7-H3 expressed on tumor cells, […]

Read more

Phase 3 Trial Evaluates Rezvilutamide vs Enzalutamide in mHSPC

/in , , /by

A pivotal new Chinese phase 3 clinical trial is poised to begin recruiting patients with metastatic hormone-sensitive prostate cancer to compare two leading androgen receptor antagonists head-to-head: rezvilutamide (SHR3680) versus enzalutamide in mHSPC. This trial represents an important milestone in prostate cancer therapeutics by directly evaluating the efficacy and safety of these oral treatments in […]

Read more

Phase 2 Trial For a New Triplet Therapy: SHR3680 (Rezvilutamide), HS-20093 and SHR2554

/in , , /by

This Phase II study investigates the efficacy and safety of three investigational agents: SHR3680 (rezvilutamide), HS-20093, and SHR2554, aiming to enhance outcomes in metastatic prostate cancer through dual-pathway inhibition. SHR3680, a selective androgen receptor (AR) antagonist, represents the latest generation of hormonal therapy designed to inhibit the AR signaling axis, a critical driver of prostate […]

Read more

Phase 1 Trial for RAD 402, Terbium Based Radioligand for Metastatic or Locally Advanced or Prostate Cancer

/in , , , , /by

Australian Human Research Ethics Committee has approved the initiation of a first‑in‑human Phase 1 therapeutic trial of RAD 402, a KLK3 (PSA)‑targeting monoclonal antibody labeled with terbium‑161 for patients with metastatic or locally advanced prostate cancer. The approval positions the program to begin site activation and enrollment in Australia, marking a notable milestone for a […]

Read more

Beyond the Primary Target: How DeepTarget Rewrites Mechanism Discovery in Cancer

/in /by

The modern small‑molecule rarely acts through a single, invariant target, and DeepTarget is a new computational framework that embraces this reality by mapping both direct and indirect anti‑cancer mechanisms across diverse cellular contexts. Developed by researchers at Sanford Burnham Prebys and collaborators, DeepTarget integrates large‑scale drug viability screens, genome‑wide CRISPR knockout data, and matched omics […]

Read more

EVOLUTION Trial Ipilimumab And Nivolumab Plus 177Lu‑PSMA‑617 in mCRPC

/in , , /by

Phase II EVOLUTION is a randomized study testing whether adding ipilimumab and nivolumab to 177Lu‑PSMA‑617 improves outcomes versus 177Lu‑PSMA‑617 alone in men with metastatic castration‑resistant prostate cancer (mCRPC). Early data presented in 2025 indicate that at 12 months, 33% of patients on the combination were free of progression versus 17% on 177Lu‑PSMA‑617 alone, signaling a […]

Read more

New Trial for AMO959 and Pluvicto and ARSI Combo

/in , , , /by

The ongoing phase Ib/II trial investigating the combination of AMO959, Pluvicto (lutetium-177 vipivotide tetraxetan, also known as AAA617 or 177Lu-PSMA-617), and androgen receptor pathway inhibitors (ARPIs) in metastatic castration-resistant prostate cancer (mCRPC) explores a novel approach targeting disease through multiple pathways. AMO959 is a direct activator of AMPK, a key metabolic regulator that can disrupt […]

Read more